BioAdaptives (OTC: BDPT) today announced the launch of Xcellara(TM) Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells’ regeneration power through a blend of adaptogens, herbs and beneficial bacteria. The innovative formulation supports the body’s natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness.
“This is an exciting milestone for BioAdaptives as we continue to push the boundaries of what’s possible in natural health supplements,” said the company’s CEO James Keener. “With the launch of Xcellara(TM) Stem Cell Activator, we’re offering a product that’s both innovative and deeply rooted in science, leveraging a sophisticated mix of adaptogens, herbs and beneficial bacteria to support and enhance the body’s healing processes.”
To view the full press release, visit https://ibn.fm/9ICPQ
About BioAdaptives Inc.
BioAdaptives is a leading innovator in the health and wellness industry, dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Its mission is to improve the quality of life for customers by offering products that support optimal health and vitality. For more information about Xcellara(TM) Stem Cell Activator and other BioAdaptives products, visit www.BioAdaptives.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the…
HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s…
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing…
Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent…
Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress…
Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of…